Pralsetinib for patients with advanced or metastatic RET-altered thyroid cancer (ARROW): a multi-cohort, open-label, registrational, phase 1/2 study

Vivek Subbiah, Mimi I. Hu, Lori J. Wirth, Martin Schuler, Aaron S. Mansfield, Giuseppe Curigliano, Marcia S. Brose, Viola W. Zhu, Sophie Leboulleux, Daniel W. Bowles, Christina S. Baik, Douglas Adkins, Bhumsuk Keam, Ignacio Matos, Elena Garralda, Justin F. Gainor, Gilberto Lopes, Chia Chi Lin, Yann Godbert, Debashis SarkerStephen G. Miller, Corinne Clifford, Hui Zhang, Christopher D. Turner, Matthew H. Taylor

Research output: Contribution to journal › Article › peer-review

Fingerprint

Dive into the research topics of 'Pralsetinib for patients with advanced or metastatic RET-altered thyroid cancer (ARROW): a multi-cohort, open-label, registrational, phase 1/2 study'. Together they form a unique fingerprint.

Medicine & Life Sciences